Endogenous Aspergillus endophthalmitis: Clinical features and treatment outcomes

Ophthalmology

Volumn 105, Issue 1, 1998, Pages 57-65

  Weishaar, Paul D ^a,f   Flynn Jr , Harry W ^a   Murray, Timothy G ^a   Davis, Janet L ^a   Barr, Charles C ^b   Gross, Jeffrey G ^c   Mein, Calvin E ^d   McLean Jr , Walter C ^e   Killian, John H ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c Carolina Retina Center   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e PA ^*

^f Bascom Palmer Eye Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CORTICOSTEROID; DEXAMETHASONE; EYE DROPS; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN;

ADULT; AGED; ARTICLE; ASPERGILLUS; CHORIORETINITIS; CILIARY DISK; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; ENDOPHTHALMITIS; ENUCLEATION; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINA DETACHMENT; SUBCONJUNCTIVAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0031895261     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)71225-3     Document Type: Article

References (37)

1. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 3rd ed. Philadelphia, WB Saunders, 1988.
2. Bennett JE. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone, 1995; v. 2, chap. 238.
3. Brod RD, Flynn HW Jr, Clarkson JG, et al. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology 1990;97:666-74.
4. Gross JG. Endogenous Aspergillus-induced endophthalmitis. Successful treatment without systemic antifungal medication. Retina 1992; 12:341-5.
5. Dimmer F. Ein Fall von Schimmelpilzerkrankung des Auges [letter]. Klin Monatsbl Augenheilkd 1913;XVI:194-204, 2 pl.
6. Naidoff MA, Green WR. Endogenous Aspergillus endophthalmitis occurring after kidney transplant. Am J Ophthalmol 1975;79:502-9.
7. Bodoia RD, Kinyoun JL, Lou QL, Bunt-Milam AH. Aspergillus necrotizing retinitis. A clinico-pathologic study and review. Retina 1989;9:226-31.
8. Darrell RW. Endogenous Aspergillus uveitis following heart surgery. Arch Ophthalmol 1967;78:354-7.
9. Graham DA, Kinyoun JL, George DP. Endogenous Aspergillus endophthalmitis after lung transplantation. Am J Ophthalmol 1995;119:107-9.
10. Hunt KE, Glasgow BJ. Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology 1996;103:757-67.
11. Kalina PH, Campbell RJ. Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia. Arch Ophthalmol 1991;109:102-3.
12. Jampol LM, Dyckman S, Maniates Z, et al. Retinal and choroidal infarction from Aspergillus: clinical diagnosis and clinicopathologic correlations. Trans Am Ophthalmol Soc 1988;86:422-40.
13. Boldrey EE. Bilateral endogenous Aspergillus endophthalmitis. Retina 1981;1:171-4.
14. Sugar HS, Mandell GH, Shalev J. Metastatic endophthalmitis associated with injection of addictive drugs. Am J Ophthalmol 1971;71:1055-8.
15. Doft BH, Clarkson JG, Rebell G, Forster RK. Endogenous Aspergillus endophthalmitis in drug abusers. Arch Ophthalmol 1980;98:859-62.
16. Denning, DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-81 (published erratum appears in Rev Infect Dis 1991;13:345).
17. Davies SF, Sarosi GA. Aspergillosis in the immunosup-pressed patient. In: Al-Doory Y, Wagner GE, eds. Aspergillosis. Springfield, IL: Thomas, 1985.
18. Michelson JB, Freedman SD, Boyden DG. Aspergillus endophthalmitis in a drug abuser. Ann Ophthalmol 1982; 14:1051-4.
19. Minamoto GY, Barlam TF, Vander Els NJ. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1992;14:66-74.
20. Pursell KJ, Telzak EE, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis 1992;14:141-8.
21. Klapholz A, Salomon N, Perlman DC, Talavera W. Aspergillosis in the acquired immunodeficiency syndrome. Chest 1991;100:1614-8.
22. Brod RD, Clarkson JG, Flynn HW Jr, Green WR. Endoge-nous fungal endophthalmitis. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology, rev. ed. Philadelphia: JB Lippincott, 1990; v. 3, chap. 11.
23. Ouano DP, Brucker AJ, Saran BR. Macular pseudohypopyon from secondary syphilis. Am J Ophthalmol 1995; 119:372-4.
24. Roney P, Barr CC, Chun CH, Raff MJ. Endogenous Aspergillus endophthalmitis. Rev Infect Dis 1986;8:955-8.
25. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15:21-34.
26. Georgiev VS. Treatment and developmental therapeutics in aspergillosis. 1. Amphotericin B and its derivatives. Respiration 1992;59:291-302.
27. Green WR, Bennett JE, Goos RD. Ocular penetration of amphotericin B. Arch Ophthalmol 1965;73:769-75.
28. Fisher JF, Taylor AT, Clark J, et al. Penetration of amphotericin B into the human eye [letter]. J Infect Dis 1983;147:164.
29. Schmitt HJ, Edwards F, Andrade J, et al. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy 1992; 38:118-26.
30. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 1994;40:92-8.
31. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrobial Agents Chemother 1987;31:6-10.
32. Maesaki S, Kohno S, Kaku M, et al. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrobial Agents Chemother 1994;38:2843-5.
33. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol 1973;76:578-83.
34. Wingard LB, Zuravleff JJ, Doft BH, et al. Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes. Invest Ophthalmol Vis Sci 1989;30:2184-9.
35. Jones BR. Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. Am J Ophthalmol 1975;79:719-51.
36. Coats ML, Peyman GA. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992;12:46-51.
37. Scherer WJ, Lee K. Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Ophthalmology 1997;104:1593-8.